These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1824647)

  • 1. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism.
    Pool JL
    Am Heart J; 1991 Jan; 121(1 Pt 2):251-9; discussion 259-60. PubMed ID: 1824647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL; Lenz ML; Taylor AA
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
    Pool JL; Taylor AA; Nelson EB
    Am J Med; 1989 Aug; 87(2A):57S-61S. PubMed ID: 2569825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
    Talseth T; Westlie L; Daae L; Vatle S
    Am Heart J; 1988 Dec; 116(6 Pt 2):1790-6. PubMed ID: 2904752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
    Trost BN; Weidmann P; Riesen W; Claessens J; Streulens Y; Nelemans F
    Am J Cardiol; 1987 May; 59(14):99G-104G. PubMed ID: 2884861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension.
    Frick MH; Cox DA; Himanen P; Huttunen M; Pitkäjärvi T; Pörsti P; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P
    Am J Cardiol; 1987 May; 59(14):61G-67G. PubMed ID: 2884854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension.
    Wessels F
    Am Heart J; 1991 Jan; 121(1 Pt 2):299-303. PubMed ID: 1824653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol.
    Taylor SH
    Am Heart J; 1991 Jan; 121(1 Pt 2):362-6. PubMed ID: 1824662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension.
    Nash DT; Schonfeld G; Reeves RL; Black H; Weidler DJ
    Am J Cardiol; 1987 May; 59(14):87G-90G. PubMed ID: 2884859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction.
    Mazzola C; Guerrasio E
    Am Heart J; 1988 Dec; 116(6 Pt 2):1797-801. PubMed ID: 2904753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up.
    Talseth T; Westlie L; Daae L
    Am Heart J; 1991 Jan; 121(1 Pt 2):280-5. PubMed ID: 1824651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension.
    Monsalve P; Vera O; Pérez Acuña F; Medina O; Ostojich K; López B; Torres N; Lugo de Franco V; Fonseca R
    Am Heart J; 1991 Jan; 121(1 Pt 2):356-61. PubMed ID: 1824661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins.
    Lehtonen A; Himanen P; Saraste M; Niittymäki K; Marniemi J
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):77S-81S. PubMed ID: 2939871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group.
    Lehtonen A
    Am Heart J; 1991 Apr; 121(4 Pt 2):1307-11. PubMed ID: 1826187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary results of the Norwegian doxazosin postmarketing surveillance study: a twelve-week experience.
    Holme I; Fauchald P; Rugstad HE; Stokke HP
    Am Heart J; 1991 Jan; 121(1 Pt 2):260-7. PubMed ID: 1824648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxazosin therapy in the treatment of diabetic hypertension.
    Feher MD
    Am Heart J; 1991 Apr; 121(4 Pt 2):1294-301. PubMed ID: 1826186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive effect of doxazosin and atenolol in short- and long-term double-blind comparison.
    Lijnen P; Fagard R; Staessen J; Amery A
    Methods Find Exp Clin Pharmacol; 1990 Oct; 12(8):563-73. PubMed ID: 2151197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension.
    Giorgi G; Legramante JM; Fioravanti G; Paies G; Legramante A
    Am Heart J; 1988 Dec; 116(6 Pt 2):1801-5. PubMed ID: 2904754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
    Hernández Hernández R; Angeli-Greaves M; Carvajal AR; Guerrero Pajuelo J; Armas Padilla MC; Armas-Hernández MJ
    Am J Hypertens; 1996 May; 9(5):437-44. PubMed ID: 8735174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.